Accordingly, PPARγ agonists were shown to inhibit STAT5A and STAT5B gene expression and to synergize with IM to eradicate resistant CML stem cells [10]. Here, STAT5B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.